wichy-shutterstock-com-1
Wichy / Shutterstock.com
29 October 2015EuropePhilip Webber

Are the Broad Institute’s CRISPR patents too broad?

The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
4 June 2018   As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.
Americas
11 March 2016   The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.
article
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

More on this story

article
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.
Americas
11 March 2016   The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.
Americas
4 June 2018   As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

More on this story

article
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.
Americas
11 March 2016   The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.
Americas
4 June 2018   As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.